BIF acquires shares in TamoRx

Booster is pleased to announce the addition of TamoRx, to the Booster Innovation Fund (BIF) portfolio.

TamoRx operates in the drug discovery part of the life sciences and medical sector. It specialises in the development of novel drugs which arm the immune system to help fight cancer. TamoRx was formed in 2021, and is classified as a seed stage, with its technology origins being from University of Auckland.

BIF has made a commitment to invest $193,000 in two tranches over the next 12 months, with the first allocation of $28,000 being settled this week and the balance estimated to be in April 2023. BIF invests alongside Brandon BioCatalyst, University of Auckland Inventors Fund and CureKids Ventures. Following settlement this week, TamoRx will represent 0.2% of BIF’s investment portfolio of 30 companies, and with a net asset value of over $12.7m.

Investors can continue to purchase units in BIF on the NZX or can subscribe for units in the fund as part of the process described in the fund’s Product Disclosure Statement (PDS) that is available at www.booster.co.nz

For further information regarding BIF visit https://www.booster.co.nz/booster-investments/booster-innovation-fund.aspx

For more information, please contact:
Gary Scott
Company Secretary
Booster Investment Management Limited
04 8944300

About Booster
Booster Investment Management Limited (Booster) is the manager and issuer of the Fund, and part of the Booster Group which has been helping New Zealanders save since 1998. The group currently administers superannuation and investment funds of over $5 billion on behalf of more than 170,000 New Zealanders.
BIF is a managed investment fund that invests in early-stage companies founded on intellectual property originated or developed in New Zealand.

For more information, including a copy of the Product Disclosure Statement and net asset value per unit, please visit www.booster.co.nz

---

Announcement PDF